Corcept Therapeutics Inc

F:HTD

Business Description

Sector

Health Care

Industry

Pharmaceuticals

Headquarters

United States of America US

Employees

730

IPO date

Apr 15, 2004

Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses.

Corcept makes money mostly by selling its medicine to specialty pharmacies and other healthcare channels, which then dispense it to patients with a doctor’s prescription. Its customers are not everyday consumers; they are hospitals, endocrinologists, specialists, pharmacies, and the patients they treat. Because these drugs are used for rare and complex conditions, Corcept’s business depends on physician adoption, patient access, and insurance coverage rather than broad retail sales.

What makes Corcept’s business model distinctive is its narrow focus on cortisol biology. Instead of being a broad pharmaceutical company, it concentrates on a small set of hormone-related diseases where it can build deep expertise and develop targeted treatments. That gives it a clear role in the healthcare value chain: it turns specialized research into niche prescription medicines for hard-to-treat endocrine disorders.